Allogene Therapeutics Equity 2024

Allogene Therapeutics Aktienanalyse

What does Allogene Therapeutics do?

Allogene Therapeutics Inc. is an innovative biotechnology company specializing in the discovery and development of therapeutic approaches for cancer patients. The company, based in South San Francisco, California, was founded in 2018 and focuses on the manufacture of allogeneic CD19 CAR-T cell therapies. Allogene Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Allogene Therapeutics's Equity

Allogene Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Allogene Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Allogene Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Allogene Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Allogene Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Allogene Therapeutics stock

What is the equity of Allogene Therapeutics this year?

Allogene Therapeutics has equity of 512.23 M USD this year.

What was the equity of Allogene Therapeutics compared to the previous year?

The equity of Allogene Therapeutics has increased/decreased by -23.08% decreased compared to the previous year.

What impact does a high equity have on investors of Allogene Therapeutics?

A high equity is advantageous for investors of Allogene Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Allogene Therapeutics?

A low equity can be a risk for investors of Allogene Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Allogene Therapeutics affect the company?

An increase in equity of Allogene Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Allogene Therapeutics affect the company?

A reduction in equity of Allogene Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Allogene Therapeutics?

Some factors that can affect the equity of Allogene Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Allogene Therapeutics so important for investors?

The equity of Allogene Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Allogene Therapeutics take to change the equity?

To change equity, Allogene Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Allogene Therapeutics pay?

Over the past 12 months, Allogene Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Allogene Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Allogene Therapeutics?

The current dividend yield of Allogene Therapeutics is .

When does Allogene Therapeutics pay dividends?

Allogene Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Allogene Therapeutics?

Allogene Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Allogene Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Allogene Therapeutics located?

Allogene Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Allogene Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Allogene Therapeutics from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.

When did Allogene Therapeutics pay the last dividend?

The last dividend was paid out on 7/17/2024.

What was the dividend of Allogene Therapeutics in the year 2023?

In the year 2023, Allogene Therapeutics distributed 0 USD as dividends.

In which currency does Allogene Therapeutics pay out the dividend?

The dividends of Allogene Therapeutics are distributed in USD.